Sandra Cuellar, PharmD, BCOP, discusses challenges with data extrapolation for biosimilars.
Sandra Cuellar, PharmD, BCOP
Advertisement
Articles by Sandra Cuellar, PharmD, BCOP
Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.
Advertisement
Latest Updated Articles
Dr. Cuellar on the Pharmacoeconomic Benefits of BiosimilarsApril 29th 2020
Dr. Cuellar on Concerns With Extrapolating Data for BiosimilarsAugust 19th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5